From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | Start of Study | Year 1 | Year 2 | Year 3 |
---|---|---|---|---|
jLS patient number | 50 (100) | 44 (88) | 39 (78) | 37 (74) |
Inactive disease | 0 | 19 (38) | 21 (42) | 24 (48) |
Remission off medicine | 0 | 0 | 0 | 10 (20) |
Disease Flare | NA | 11 (22) | 10 (20) | 6 (12) |
Adverse Event ≥ grade 2 | NA | 21 (42) | 12 (24) | 7 (14) |
PGA-A (IQR) | 5 (4-6) | 1 (0-2) | 0 (0-1.3) | 0 (0-1) |
mLoSSI (IQR) | 7 (4-10) | 0 (0-1) | 0 (0-0) | 0 (0-0) |
LSCAM (IQR) | 7 (4-13.3) | 2 (0-4) | 0 (0-2) | 0 (0-2) |